首页> 外文期刊>Advances in Bioscience and Clinical Medicine >A comparison of Oral and Inhalant Corticosteroids in Treatment of Mild to Moderate Asthma Exacerbation in Children
【24h】

A comparison of Oral and Inhalant Corticosteroids in Treatment of Mild to Moderate Asthma Exacerbation in Children

机译:口服和吸入性糖皮质激素治疗儿童轻度至中度哮喘急性发作的比较

获取原文
       

摘要

Introduction: Oral corticosteroids are the main treatment in asthma exacerbation. It has been reported that inhaled corticosteroids can be used instead of oral corticosteroids in asthma exacerbation. We aimed to evaluate the efficacy of inhaled fluticasone and oral prednisolone in children with mild to moderate asthma exacerbation. Materials and Methods: In this randomized clinical trial, 60 children with mild-to-moderate acute asthma exacerbation visiting emergency department were randomly assigned to receive oral prednisolone (2 mg/kg) or fluticasone spray (2 puffs every 12 hours, each puff contains 250 microgram fluticasone) using an spacer for one week. The first dose of the treatment was given in the emergency department. Children were followed for seven days and signs and symptoms of exacerbation, as well as spirometry findings were evaluated. Results: On the days 1 and 3, symptoms including cough, sputum and need for salbutamol during day was more improved in oral prednisolone and symptoms at night was more improved in inhaled fluticasone. Patients were almost symptom free on the seventh day. Forced expiratory volume in 1 second, forced vital capacity and forced expiratory flow rate on the seventh day were significantly better with inhaled fluticasone compared to oral prednisolone. Conclusion: Both inhaled fluticasone and oral prednisolone improved symptoms during a week after exacerbation; however, better respiratory function in children treated with inhaled fluticasone is indicative of its further efficacy compared to oral prednisolone. Considering the low systemic effects of inhaled fluticasone, this treatment seems to be more appropriate in treatment of mild to moderate exacerbations.
机译:简介:口服皮质类固醇激素是哮喘急性发作的主要治疗方法。据报道,哮喘发作加重时,可使用吸入皮质类固醇代替口服皮质类固醇。我们旨在评估吸入氟替卡松和口服泼尼松龙对轻度至中度哮喘急性发作儿童的疗效。材料和方法:在这项随机临床试验中,将60例轻度至中度急性哮喘发作的儿童随机分到急诊科接受口服泼尼松龙(2 mg / kg)或氟替卡松喷雾(每12小时2抽吸一次,每个抽吸一次) 250微克氟替卡松),隔片放置一周。急诊室给予了第一剂治疗。跟踪儿童7天,评估病情加重的症状和体征以及肺活量测定结果。结果:在口服泼尼松龙的第1天和第3天,包括咳嗽,痰和白天沙丁胺醇的需求症状得到了改善,而吸入氟替卡松的症状则得到了改善。第七天患者几乎没有症状。与口服泼尼松龙相比,吸入氟替卡松在1秒内的强制呼气量,在第七天的强制肺活量和强制呼气流速明显更好。结论:吸入氟替卡松和口服泼尼松龙可在病情加重后的一周内改善症状。然而,与口服泼尼松龙相比,吸入氟替卡松治疗的儿童呼吸功能改善表明其进一步的疗效。考虑到吸入氟替卡松的全身作用低,这种治疗似乎更适合于轻度至中度加重。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号